Breaking News

Irisys Receives NIH Contract for the Formulation of Drinabant

Seeks to develop a drug for treatment of acute cannabinoid overdose.

By: Contract Pharma

Contract Pharma Staff

Irisys LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, has been awarded a contract valued at $850,000 by the National Center for Advancing Translational Sciences (NCATS), one of 27 institutes of the NIH, to develop a new injectable formulation of drinabant, a selective, high affinity cannabinoid receptor (CB-1) antagonist.    Opiant Pharmaceuticals Inc., an NCATS collaborator, licensed drinabant from Sanofi and is developing it with the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters